OTCMKTS:WNDM

Wound Management Technologies Competitors

$30.25
+0.40 (+1.34 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$29.72
Now: $30.25
$30.99
50-Day Range
$0.05
MA: $26.38
$33.98
52-Week Range
$0.02
Now: $30.25
$0.10
Volume27,989 shs
Average Volume137,966 shs
Market Capitalization$7.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.9

Competitors

Wound Management Technologies (OTCMKTS:WNDM) Vs. STE, SNN, WILYY, SHWGF, MSA, and AVNS

Should you be buying WNDM stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Wound Management Technologies, including STERIS (STE), Smith & Nephew (SNN), Demant A/S (WILYY), Shandong Weigao Group Medical Polymer (SHWGF), MSA Safety (MSA), and Avanos Medical (AVNS).

STERIS (NYSE:STE) and Wound Management Technologies (OTCMKTS:WNDM) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Risk and Volatility

STERIS has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500. Comparatively, Wound Management Technologies has a beta of 1.9, meaning that its stock price is 90% more volatile than the S&P 500.

Earnings and Valuation

This table compares STERIS and Wound Management Technologies' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
STERIS$3.03 billion5.86$407.61 million$5.6436.90
Wound Management Technologies$5.84 million1,225.76$-600,000.00N/AN/A

STERIS has higher revenue and earnings than Wound Management Technologies.

Profitability

This table compares STERIS and Wound Management Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
STERIS13.97%14.44%9.32%
Wound Management Technologies-10.28%-39.28%-21.49%

Analyst Ratings

This is a breakdown of recent recommendations for STERIS and Wound Management Technologies, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
STERIS02302.60
Wound Management Technologies0000N/A

STERIS currently has a consensus target price of $214.25, suggesting a potential upside of 2.94%. Given STERIS's higher possible upside, equities analysts plainly believe STERIS is more favorable than Wound Management Technologies.

Institutional & Insider Ownership

90.0% of STERIS shares are owned by institutional investors. 1.2% of STERIS shares are owned by insiders. Comparatively, 75.4% of Wound Management Technologies shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

STERIS beats Wound Management Technologies on 8 of the 11 factors compared between the two stocks.

Wound Management Technologies (OTCMKTS:WNDM) and Smith & Nephew (NYSE:SNN) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Volatility & Risk

Wound Management Technologies has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Smith & Nephew has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and target prices for Wound Management Technologies and Smith & Nephew, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wound Management Technologies0000N/A
Smith & Nephew24602.33

Smith & Nephew has a consensus price target of $47.1667, indicating a potential upside of 16.75%. Given Smith & Nephew's higher probable upside, analysts clearly believe Smith & Nephew is more favorable than Wound Management Technologies.

Insider & Institutional Ownership

8.9% of Smith & Nephew shares are owned by institutional investors. 75.4% of Wound Management Technologies shares are owned by company insiders. Comparatively, 1.0% of Smith & Nephew shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Wound Management Technologies and Smith & Nephew's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wound Management Technologies$5.84 million1,225.76$-600,000.00N/AN/A
Smith & Nephew$5.14 billion3.46$600 million$2.0419.80

Smith & Nephew has higher revenue and earnings than Wound Management Technologies.

Profitability

This table compares Wound Management Technologies and Smith & Nephew's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wound Management Technologies-10.28%-39.28%-21.49%
Smith & NephewN/AN/AN/A

Summary

Smith & Nephew beats Wound Management Technologies on 8 of the 11 factors compared between the two stocks.

Demant A/S (OTCMKTS:WILYY) and Wound Management Technologies (OTCMKTS:WNDM) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, dividends, earnings and risk.

Volatility & Risk

Demant A/S has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Wound Management Technologies has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Demant A/S and Wound Management Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Demant A/S03002.00
Wound Management Technologies0000N/A

Earnings & Valuation

This table compares Demant A/S and Wound Management Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Demant A/S$2.24 billion5.35$219.15 million$0.4555.36
Wound Management Technologies$5.84 million1,225.76$-600,000.00N/AN/A

Demant A/S has higher revenue and earnings than Wound Management Technologies.

Profitability

This table compares Demant A/S and Wound Management Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Demant A/SN/AN/AN/A
Wound Management Technologies-10.28%-39.28%-21.49%

Summary

Demant A/S beats Wound Management Technologies on 5 of the 7 factors compared between the two stocks.

Wound Management Technologies (OTCMKTS:WNDM) and Shandong Weigao Group Medical Polymer (OTCMKTS:SHWGF) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership.

Earnings & Valuation

This table compares Wound Management Technologies and Shandong Weigao Group Medical Polymer's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wound Management Technologies$5.84 million1,225.76$-600,000.00N/AN/A
Shandong Weigao Group Medical Polymer$1.50 billion5.04$266.95 millionN/AN/A

Shandong Weigao Group Medical Polymer has higher revenue and earnings than Wound Management Technologies.

Analyst Ratings

This is a breakdown of current ratings for Wound Management Technologies and Shandong Weigao Group Medical Polymer, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wound Management Technologies0000N/A
Shandong Weigao Group Medical Polymer0000N/A

Profitability

This table compares Wound Management Technologies and Shandong Weigao Group Medical Polymer's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wound Management Technologies-10.28%-39.28%-21.49%
Shandong Weigao Group Medical PolymerN/AN/AN/A

Risk & Volatility

Wound Management Technologies has a beta of 1.9, indicating that its stock price is 90% more volatile than the S&P 500. Comparatively, Shandong Weigao Group Medical Polymer has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Summary

Shandong Weigao Group Medical Polymer beats Wound Management Technologies on 5 of the 7 factors compared between the two stocks.

MSA Safety (NYSE:MSA) and Wound Management Technologies (OTCMKTS:WNDM) are both mid-cap industrial products companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

Profitability

This table compares MSA Safety and Wound Management Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
MSA Safety10.40%23.96%10.13%
Wound Management Technologies-10.28%-39.28%-21.49%

Analyst Recommendations

This is a summary of recent ratings for MSA Safety and Wound Management Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
MSA Safety01202.67
Wound Management Technologies0000N/A

MSA Safety presently has a consensus target price of $151.50, suggesting a potential downside of 2.65%. Given MSA Safety's higher probable upside, research analysts plainly believe MSA Safety is more favorable than Wound Management Technologies.

Insider & Institutional Ownership

77.2% of MSA Safety shares are owned by institutional investors. 7.0% of MSA Safety shares are owned by company insiders. Comparatively, 75.4% of Wound Management Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Volatility and Risk

MSA Safety has a beta of 0.96, meaning that its share price is 4% less volatile than the S&P 500. Comparatively, Wound Management Technologies has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500.

Valuation & Earnings

This table compares MSA Safety and Wound Management Technologies' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MSA Safety$1.40 billion4.34$136.44 million$4.8032.42
Wound Management Technologies$5.84 million1,225.76$-600,000.00N/AN/A

MSA Safety has higher revenue and earnings than Wound Management Technologies.

Summary

MSA Safety beats Wound Management Technologies on 8 of the 11 factors compared between the two stocks.

Wound Management Technologies (OTCMKTS:WNDM) and Avanos Medical (NYSE:AVNS) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Profitability

This table compares Wound Management Technologies and Avanos Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Wound Management Technologies-10.28%-39.28%-21.49%
Avanos Medical1.93%3.20%2.28%

Insider and Institutional Ownership

94.8% of Avanos Medical shares are held by institutional investors. 75.4% of Wound Management Technologies shares are held by insiders. Comparatively, 1.5% of Avanos Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Wound Management Technologies has a beta of 1.9, indicating that its share price is 90% more volatile than the S&P 500. Comparatively, Avanos Medical has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500.

Valuation & Earnings

This table compares Wound Management Technologies and Avanos Medical's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Wound Management Technologies$5.84 million1,225.76$-600,000.00N/AN/A
Avanos Medical$697.60 million3.10$-45,900,000.00$1.0742.04

Wound Management Technologies has higher earnings, but lower revenue than Avanos Medical.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Wound Management Technologies and Avanos Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Wound Management Technologies0000N/A
Avanos Medical10102.00

Avanos Medical has a consensus price target of $50.00, suggesting a potential upside of 11.16%. Given Avanos Medical's higher probable upside, analysts clearly believe Avanos Medical is more favorable than Wound Management Technologies.

Summary

Avanos Medical beats Wound Management Technologies on 7 of the 11 factors compared between the two stocks.


Wound Management Technologies Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
STERIS logo
STE
STERIS
2.1$208.14+0.7%$17.77 billion$3.03 billion42.22Analyst Downgrade
Increase in Short Interest
Smith & Nephew logo
SNN
Smith & Nephew
2.1$40.40+1.7%$17.75 billion$5.14 billion19.80Unusual Options Activity
Analyst Revision
News Coverage
Demant A/S logo
WILYY
Demant A/S
0.8$24.91+4.1%$11.99 billion$2.24 billion55.36Analyst Upgrade
High Trading Volume
Increase in Short Interest
SHWGF
Shandong Weigao Group Medical Polymer
0.0$1.67+0.0%$7.55 billion$1.50 billion0.00Increase in Short Interest
MSA Safety logo
MSA
MSA Safety
2.1$155.63+1.1%$6.08 billion$1.40 billion44.09
Avanos Medical logo
AVNS
Avanos Medical
1.5$44.98+1.6%$2.16 billion$697.60 million155.10Gap Down
Eargo logo
EAR
Eargo
1.0$47.01+2.0%$1.80 billionN/A0.00High Trading Volume
Increase in Short Interest
Lockup Expiration
Establishment Labs logo
ESTA
Establishment Labs
1.2$69.19+4.2%$1.63 billion$89.57 million-40.94Decrease in Short Interest
Inogen logo
INGN
Inogen
1.2$65.73+0.4%$1.47 billion$361.94 million-730.25Insider Selling
Analyst Revision
News Coverage
Sientra logo
SIEN
Sientra
1.6$7.07+0.4%$404.92 million$83.70 million-3.97Analyst Upgrade
Increase in Short Interest
Invacare logo
IVC
Invacare
1.6$8.79+1.1%$302.59 million$927.96 million-7.15Analyst Downgrade
SMTI
Sanara MedTech
0.8$30.25+1.3%$230.41 million$11.77 million-23.45Decrease in Short Interest
Gap Down
Lakeland Industries logo
LAKE
Lakeland Industries
1.8$27.36+3.4%$219.43 million$107.81 million7.77Earnings Announcement
Analyst Report
News Coverage
Gap Down
Surgalign logo
SRGA
Surgalign
1.7$1.89+2.1%$208.41 million$308.38 million-1.05Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.89+2.1%$208.41 million$308.38 million-1.05Increase in Short Interest
United Health Products logo
UEEC
United Health Products
1.0$0.91+2.2%$205.54 millionN/A-15.16Gap Up
Milestone Scientific logo
MLSS
Milestone Scientific
1.3$2.67+7.5%$177.71 million$8.38 million-16.69News Coverage
Conformis logo
CFMS
Conformis
1.3$0.85+2.4%$154.50 million$77.43 million-2.49Gap Up
Nutriband logo
NTRB
Nutriband
0.7$20.99+0.0%$133.41 million$370,000.00-69.96Upcoming Earnings
Alpha Pro Tech logo
APT
Alpha Pro Tech
2.0$9.76+2.8%$132.71 million$46.67 million6.68Decrease in Short Interest
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.84+1.6%$84.81 million$4.87 million-1.46Decrease in Short Interest
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$14.45+1.0%$81.93 million$2.32 million-7.23Analyst Downgrade
Decrease in Short Interest
Myomo logo
MYO
Myomo
1.2$10.15+2.3%$56.67 million$3.84 million-1.11Gap Down
Predictive Oncology logo
POAI
Predictive Oncology
1.3$1.08+4.6%$52.70 million$1.41 million-0.17News Coverage
Gap Down
AHPI
Allied Healthcare Products
0.5$4.48+3.3%$17.97 million$31.89 million0.00
Bionik Laboratories logo
BNKL
Bionik Laboratories
0.7$2.72+5.1%$13.61 million$2.15 million-0.55News Coverage
Gap Down
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.85+0.0%$11.39 million$530,000.00-1.42Decrease in Short Interest
Gap Up
Advanced Biomedical Technologies logo
ABMT
Advanced Biomedical Technologies
0.0$0.11+0.0%$7.44 million$10,000.000.00
AVTI
Avitar
0.5$0.00+0.0%$0.00N/A0.00Gap Up
PFND
Pathfinder Cell Therapy
0.0$0.01+0.0%$0.00N/A0.00
PCGR
PC Group
0.2$0.00+0.0%$0.00N/A0.00
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.